Gold tier: mechanically validated evidence, with its primary source.
49 evidence items · page 2 / 2
59.2 %Of the 135 HPV-positive women who were notified of their results, 77 (59.2%) sought treatment.
Kenyainfection à HPVobserved 2018published 2021International journal of gynaecology and obstetrics: the official organ of the InternationPubMeddocument of 7 observations
90 %The rate of HPV seropositivity at 48 months was 90% for HPV-16.
Kenyainfection à HPVobserved 48 monthspublished 2021VaccinePubMeddocument of 7 observations
1,002 womenHome-based testing reached 1002 women aged 25–65 years in six communities in rural Western Kenya.
Kenyainfection à HPVpublished 2020BMJ openPubMeddocument of 4 observations
293 casesA total of 293 HPV-positive women living with HIV underwent thermal ablation in the study period.
Kenyainfection à HPVobserved August 2019 to February 2020published 2020JCO global oncologyPubMeddocument of 14 observations
84.3 %Among 115 gbMSM in Nairobi, Kenya, HPV prevalence was 84.3% among those living with HIV.
Kenyainfection à HPVpublished 2023Cancer medicinePubMeddocument of 7 observations
The prevalence of high-risk HPV genotypes was statistically higher in the Botswana population compared to Kenya (p-value < 0.001).
Botswana · Kenyainfection à HPVpublished 2022BMC infectious diseasesPubMeddocument of 4 observations
9.4 %HPV vaccination coverage was 9.4% among adolescent girls in Western Kenya.
Kenyainfection à HPVpublished 2021The Pan African medical journalPubMeddocument of 5 observations
32.2 %Among 115 gbMSM in Nairobi, Kenya, one-third (32.2%) had high-risk HPV (HR-HPV).
Kenyainfection à HPVpublished 2023Cancer medicinePubMeddocument of 7 observations
47.6 %Among participants with high-risk HPV genotypes (n=82), 47.6% (39/82) were coinfected with HIV.
Kenyainfection à HPV · VIH/sidapublished 2022BMC infectious diseasesPubMeddocument of 4 observations
83 %The rate of HPV seropositivity at 48 months was 83% for HPV-6.
Kenyainfection à HPVobserved 48 monthspublished 2021VaccinePubMeddocument of 7 observations
42 %HPV vaccination could reduce the cervical cancer burden by 42–60 %.
Kenyacancer du col de l'utérus · infection à HPVpublished 2023VaccinePubMeddocument of 6 observations
75.84 %75.84% of health-care professionals thought that giving a single-dose of the HPV vaccine to adolescent girls and young women was either acceptable or very acceptable.
Kenyainfection à HPVpublished 2024Journal of the National Cancer Institute. MonographsPubMeddocument of 5 observations
97 daysHPV-positive women who did not receive treatment had a median time from screening to result notification of 97 days.
Kenyainfection à HPVobserved 2018published 2021International journal of gynaecology and obstetrics: the official organ of the InternationPubMeddocument of 7 observations
77 %The rate of HPV seropositivity at 48 months was 77% for HPV-18.
Kenyainfection à HPVobserved 48 monthspublished 2021VaccinePubMeddocument of 7 observations
92 daysHPV-positive women who received treatment had a median time from screening to result notification of 92 days.
Kenyainfection à HPVobserved 2018published 2021International journal of gynaecology and obstetrics: the official organ of the InternationPubMeddocument of 7 observations
16 %In 2020, only 16% of the targeted population in Kenya returned for the second dose of the HPV vaccine.
Kenyainfection à HPVobserved 2020published 2022Frontiers in public healthPubMeddocument of 4 observations
16.3 %Among 98 HPV-positive cervical samples, 16.3% (16/98) had low-risk (LR) HPV genotypes.
Kenyainfection à HPVpublished 2022BMC infectious diseasesPubMeddocument of 4 observations
16.8 %Among 555 women (16.8%) who tested HPV-positive, 257 (46.3%) accessed treatment.
Kenyainfection à HPVpublished 2024BMC women's healthPubMeddocument of 5 observations
10 %Only 10% (105 out of 1027) of HPV-positive cases were triaged with VIA/VILI.
Kenyainfection à HPVpublished 2023PloS onePubMeddocument of 16 observations
22.4 %Women in the general population had an HPV positivity rate of 22.4%.
Kenyainfection à HPVpublished 2026BMC cancerPubMeddocument of 12 observations
10.3 %Women who reported engaging in commercial sex were less likely to test HPV positive compared to women in the general population (10.3% versus 22.4%, respectively).
Kenyainfection à HPVpublished 2026BMC cancerPubMeddocument of 12 observations
33 %In 2020, only 33% of the targeted population in Kenya received the first dose of the HPV vaccine.
Kenyainfection à HPVobserved 2020published 2022Frontiers in public healthPubMeddocument of 4 observations
18.7 %Among the 749 women screened, 134 women (18.7%) were HPV-positive.
Kenyainfection à HPVpublished 2022BMC women's healthPubMeddocument of 7 observations
16 %A study from Kenya reported a low HPV vaccine second dose uptake of 16% in young girls during the COVID-19 pandemic.
Kenyainfection à HPVHAL · Unilimdocument of 69 observations
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.